# Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

> **NCT07501169** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 33 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Sacituzumab Tirumotecan and Anlotinib

## Key facts

- **NCT ID:** NCT07501169
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07501169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07501169, "Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07501169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*